Seladelpar Sulfoxide Impurity-3

Seladelpar Sulfoxide Impurity-3 is a process-related impurity associated with the drug Seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist developed for the treatment of primary biliary cholangitis (PBC). This impurity typically forms through oxidation of the parent compound, where a sulfur-containing moiety is converted into a sulfoxide group. As a sulfoxide impurity, it is monitored during pharmaceutical manufacturing and stability studies to ensure product purity, safety, and regulatory compliance according to ICH impurity guidelines. Control of such impurities is essential because they may affect drug efficacy, stability, or toxicity if present above acceptable limits.